title: Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations.
abstract: Therapeutic vaccinations using human immunodeficiency virus (HIV) antigens in HIV-infected patients on antiretroviral therapy (ART) have so far been attempted with the purpose of inducing CTL response. However, they can also be useful as a strategy for activation of latent HIV reservoir, which is thought to be mainly comprised of latently infected HIV-specific memory CD4 cells, eventually leading to elimination of the virus. The present study was carried out to explore the ability of different HIV antigens to activate HIV replication as assessed by intracellular P24 detection as well as to induce T cell responses in terms of cytokine expression by flow cytometry after stimulation of PBMCs from HIV-infected patients. HIV antigens were found to be able to activate most of the CD4 T cells harboring proviral DNA. HIV-1 Pol and Env were responsible for induction of higher HIV replication in terms of both magnitude and frequency followed by Gag and Nef. As opposed to this, Pol and Env contributed to fewer numbers of polyfunctional CD8 cells desirable for elimination of HIV-infected cells in comparison to Gag and Nef. Thus, HIV antigens may provide a strategy for the activation of a latent reservoir. It was observed that HIV replication started as early as half an hour after in vitro activation indicating a stringent need for maintaining effective concentrations of antiretroviral drugs to prevent further spread of HIV during this process. HIV-infected cells were found to be responsible for higher IL-10 secretion after activation, which could also serve as one of the reasons for suppressed CD8 responses to Pol and Env as more HIV-infected CD4 cells would be secreting IL-10 in response to these antigens. Since IL-10 blockade helped to improve immune responses in terms of cytokine secretion, it should be considered in settings of therapeutic vaccination to improve CTL responses, which will ultimately limit the persistence of the viral reservoir.
authors.affiliation: National AIDS Research Institute, Pune, India.
authors.forename: Ashwini
authors.initials: A
authors.lastname: Shete
authors.forename: Madhuri
authors.initials: M
authors.lastname: Thakar
authors.forename: Dharmesh P
authors.initials: DP
authors.lastname: Singh
authors.forename: Raman
authors.initials: R
authors.lastname: Gangakhedkar
authors.forename: Asmita
authors.initials: A
authors.lastname: Gaikwad
authors.forename: Jyoti
authors.initials: J
authors.lastname: Pawar
authors.forename: Ramesh
authors.initials: R
authors.lastname: Paranjape
mesh_terms: D016915:AIDS Vaccines; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D016207:Cytokines / Q000378:metabolism; D005434:Flow Cytometry; D006678:HIV / Q000502:physiology*; D015488:HIV Antigens / Q000276:immunology*; D016655:HIV Core Protein p24 / Q000378:metabolism*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D006801:Humans; D014611:Vaccination; D014779:Virus Replication
chemical_list: D016915:AIDS Vaccines; D044966:Anti-Retroviral Agents; D016207:Cytokines; D015488:HIV Antigens; D016655:HIV Core Protein p24